Pre-made Cusatuzumab benchmark antibody ( Whole mAb, anti-CD70/CD27-L therapeutic antibody, Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Cusatuzumab biosimilar, Whole mAb, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-127-1mg	1mg	3090
GMP-Bios-ab-127-10mg	10mg	Inquiry
GMP-Bios-ab-127-100mg	100mg	Inquiry
GMP-Bios-ab-127-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cusatuzumab biosimilar, Whole mAb, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody
INN Name	Cusatuzumab
Target	CD27-L
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	arGEN-X
Conditions Approved	na
Conditions Active	Cutaneous T-cell lymphoma;Acute myeloid leukaemia;Haematological malignancies;Myelodysplastic syndromes;Solid tumours
Conditions Discontinued	Nasopharyngeal cancer;Autoimmune disorders
Development Tech	POTELLIGENT Technology;SIMPLE Antibody Technology